Canada Welcomes Its First Generic Semaglutide
In September 2026, Sandoz Canada announced that Health Canada has granted regulatory approval for its generic version of semaglutide (PrSandoz® Semaglutide). This is a generic version of the well-known brand-name drug Ozempic®, marking a significant lower-cost alternative in the treatment landscape for type 2 diabetes in Canada.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally approved for the treatment of adults with type 2 diabetes. It works by mimicking the action of an intestinal hormone, helping the pancreas release more insulin when blood sugar rises while suppressing glucagon secretion, thereby improving glycemic control. In recent years, the drug has also gained widespread attention for its significant effects on weight loss.
The approved generic semaglutide is administered once weekly by injection and should be used alongside diet and exercise. Health Canada issued a Notice of Compliance for three doses delivered subcutaneously via two pen presentations: a pen delivering 0.25 mg or 0.5 mg doses, and a pen delivering 1 mg doses.
Indications and Treatment Options
According to the approved indications, generic semaglutide can be used for glycemic control in adult patients with type 2 diabetes in the following scenarios:
- As monotherapy with diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance
- In combination with metformin when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control
- In combination with metformin and a sulfonylurea when dual therapy does not achieve adequate glycemic control
- In combination with metformin or a sulfonylurea and an SGLT2 inhibitor when triple therapy does not achieve adequate glycemic control
- In combination with basal insulin and metformin when dual therapy does not achieve adequate glycemic control
Why Does This Approval Matter?
According to Sandoz Canada, close to 12 million semaglutide injection pens are used annually in Canada, with demand continuing to rise significantly. The launch of a generic version is expected to reduce barriers to access both financially and in terms of supply.
"This milestone reinforces the Sandoz Purpose of pioneering access for patients," says Michel Robidoux, President and General Manager of Sandoz Canada. "With the upcoming launch of this product, we aim to reduce barriers to access, both financially and in terms of supply."
As a Canadian leader in off-patent medicines, Sandoz Canada has a product portfolio of over 700 generics and biosimilars spanning multiple therapeutic areas including anti-infective, cardiovascular, central nervous system, diabetes, immunology, and oncology. In 2025, 59 million Sandoz prescriptions were issued in Canada.
Patient Support and Educational Resources
To support the introduction of generic semaglutide, Sandoz Canada is developing educational materials and practical tools designed to support patients and healthcare professionals throughout their treatment journey. The Product Monograph will be made publicly available through Health Canada's Drug Product Database upon regulatory approval.
Everyday Blood Sugar Management Tips
For people living with type 2 diabetes, medication is only one part of disease management. The following daily habits are equally important:
- Monitor blood sugar regularly: Check fasting and post-meal blood glucose as recommended by your doctor to understand your patterns
- Eat a balanced diet: Control carbohydrate intake, increase dietary fiber, and avoid high-sugar and high-fat foods
- Stay active: Aim for at least 150 minutes of moderate-intensity aerobic exercise per week, such as brisk walking or swimming
- Schedule regular check-ups: Test HbA1c every 3-6 months to assess long-term glycemic control
- Manage your weight: Losing 5%-10% of body weight can significantly improve blood sugar for overweight or obese patients
The Xiaoshu Health App can sync with Apple Health to track relevant metrics, helping you record blood sugar, weight, and exercise data for more intuitive and convenient diabetes management.